Literature DB >> 22425613

Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.

Y S Chong1, Y K Kim, M W Lee, S H Kim, W J Lee, H C Rhim, S J Lee.   

Abstract

AIM: To examine the differential features of mass-forming intrahepatic cholangiocarcinoma (ICC) from atypical hypovascular hepatocellular carcinoma (HCC) on gadoxetic acid-enhanced magnetic resonance imaging (MRI).
MATERIALS AND METHODS: The institutional review board approved this retrospective study and waived informed patient consent. Seventy patients with pathologically proven ICCs (35) and hypovascular atypical HCCs (35) who had undergone preoperative gadoxetic acid-enhanced MRI were enrolled in this study. Images were analysed for the shape of the lesions and presence of hyperintensity on the T1-weighted image (T1WI) and hypo- or hyperintense areas on the T2-weighted image (T2WI). In addition, images were analysed for the presence of linear hyperintensity or multifocal, tiny, hyperintense foci on T2WI and the presence of rim enhancement during early dynamic phases and a central enhancement with a hypointense rim (target appearance) on the 10 and 20 min hepatobiliary phase images. The significance of these findings was determined by the X(2) test.
RESULTS: Univariate analysis revealed that the following significant parameters favour ICC or hypovascular HCC; the presence of T2 hypo- and hyperintense areas and target appearance on the 10 min hepatobiliary phase images favour ICC, and the presence of T2 linear hyperintensity and T2 multifocal hyperintense foci favour hypovascular HCC (p < 0.05). Multivariate analysis revealed that only target appearance on the 10 min hepatobiliary phase was predictive of ICC (p = 0.002) as 30 ICCs (85.7%) showed this feature. However, the target appearance was also observed in all six scirrhous HCCs.
CONCLUSION: A target appearance on the 10 min hepatobiliary phase images is the best predictor for identifying mass-forming ICC at gadoxetic acid-enhanced MRI.
Copyright © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425613     DOI: 10.1016/j.crad.2012.01.004

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  28 in total

1.  Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.

Authors:  Rihyeon Kim; Jeong Min Lee; Cheong-Il Shin; Eun Sun Lee; Jeong Hee Yoon; Ijin Joo; Seong Ho Kim; Inpyeong Hwang; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-09-15       Impact factor: 5.315

2.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

3.  Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI.

Authors:  Jiyoung Hwang; Young Kon Kim; Ji Hye Min; Seo-Youn Choi; Woo Kyung Jeong; Seong Sook Hong; Hyun-Joo Kim; Soohyun Ahn; Hyeon Seon Ahn
Journal:  Eur Radiol       Date:  2017-05-12       Impact factor: 5.315

Review 4.  Differentiation of hepatocellular carcinoma from its various mimickers in liver magnetic resonance imaging: What are the tips when using hepatocyte-specific agents?

Authors:  Yang Shin Park; Chang Hee Lee; Jeong Woo Kim; Sora Shin; Cheol Min Park
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  The treatment of cholangiocarcinoma: a hepatologist's perspective.

Authors:  Kamran Qureshi; Randhir Jesudoss; Abdullah M S Al-Osaimi
Journal:  Curr Gastroenterol Rep       Date:  2014-10

Review 6.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

Review 7.  [Radiological diagnostic workup of liver tumors].

Authors:  H-J Raatschen
Journal:  Internist (Berl)       Date:  2020-02       Impact factor: 0.743

Review 8.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 9.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

10.  Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis.

Authors:  Hyun Jeong Park; Kyung Mi Jang; Tae Wook Kang; Kyoung Doo Song; Seong Hyun Kim; Young Kon Kim; Dong Ik Cha; Joungyoun Kim; Juna Goo
Journal:  Eur Radiol       Date:  2015-12-03       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.